BDA finishes fiscal 2021 on a high
3 minute read
Fiscal 2021 sales figures released by medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX:BDA) could well be the catalyst for a substantial share price rerating given that they represent record medicinal cannabis sales growth during FY2021.
During the period, BDA dispensed a total of 12,187 products, which marks a 212% increase on the previous corresponding period (FY2020: 3,907).
The company also delivered 17% quarter-on-quarter growth during the June quarter of fiscal 2021 following the sale of 4,441 units (March quarter FY2021: 3,805).
In a major achievement, BDA retained a 46% share of the total Australian market for full plant high CBD products during FY2021 based on data that was available up to and including May 2021.
Importantly, this was assisted by positive momentum during the last six months of the period.
The following graph illustrates the robust quarterly medicinal cannabis products sales by unit during fiscal 2021.
BDA benefiting from repeat business
Underlining the level of consumer loyalty, 65% of prescriptions sold during FY2021 were repeat prescriptions, highlighting the quality of the medicines and the ongoing satisfaction and benefits both patients and physicians are witnessing with the use of BDA’s medicinal cannabis products on a range of conditions.
The significant growth in prescription volumes was supported by the company’s ongoing educational initiatives with healthcare professionals, as well as BDA’s nationwide clinical study investigating the efficacy of Bod’s medicinal cannabis products when prescribed for debilitating conditions, including anxiety, insomnia and Post Traumatic Stress Disorder (PTSD).
In July last year, Bod commenced an Australia-wide, multi-clinic, open-label observational study into the effectiveness of its medicinal cannabis range, MediCabilisTM, for indications including anxiety disorders, insomnia and Post Traumatic Stress Disorder.
The study aims to collect data from 500 patients who will be prescribed MediCabilisTM over a 12- month period with the aim of generating insights into the efficacy of the product on patients suffering from particular conditions.
Management expects momentum to continue
Bod has now sold a total of 16,267 medicinal cannabis product units since first prescriptions in 2019 and management expects this strong growth to continue over the coming months and beyond.
Medicinal cannabis sales will materially add to the BDA’s revenue profile, and the company is continuing to scale up operations across Australia and the United Kingdom to underpin its upward trajectory and increase overall market share.
The following graph shows the cumulative medicinal cannabis products sold since June 2019 with a particular highlight being the acceleration that has occurred in the last 12 months.
Discussing the impressive sales performance and pointing to opportunities and upcoming initiatives that are likely to support sustained momentum, chief executive Jo Patterson said, “BDA continues to achieve a very strong upward trajectory through its medicinal cannabis operations on both a quarter-on-quarter and a year-on-year basis.
"These sales will further contribute to the company’s growing revenue profile.
"During FY2021, the company maintained a near 50% market share for the total addressable market for high CBD products in Australia.
"While repeat prescriptions remained at a high level, Bod also increased its patient and doctor acquisitions through ongoing educational initiatives and its relationships with approved prescribers.
"We anticipate increased demand for our medicinal cannabis product suite over the coming quarter and beyond.
"A number of new products are currently being introduced and operations in the UK continue to scale pleasingly.
"We look forward to updating shareholders on further growth as it materialises.”
View Our Investment Portfolios
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction
is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
